PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel

Heart Centre Rotenburg

Status and phase

Completed

Phase 2

Conditions

Coronary Stenosis

Treatments

Device: Drug Eluting Balloon

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00404144

ID: BBM-VS-52

PEPCAD II/CRI/05/-01/c-c

Details and patient eligibility

About

The objective of this study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon catheter (3µg/mm2 balloon surface area) in the treatment of significant (≥ 70% and < 100 %) stenoses in native coronary arteries with reference diameters from 2.25 mm to 2.8 mm and ≤ 22 mm in length for procedural success and preservation of vessel patency.

Full description

Background information:

Stent deployment for the treatment of coronary artery stenoses has evolved as the standard treatment in nearly all types of coronary lesions over the past two decades. The initial recurrence rate of bare stents in the range of 20 30 % in low risk stenoses has been further reduced by devices with passive coatings such as silicon carbide, heparin, phosphorylcholine, and carbon.

In the percutaneous transluminal treatment of stenotic coronary arteries with diameters below 3 mm, however, none of the currently available methods, namely balloon angioplasty with conventional balloons (POBA) and deployment of non-drug eluting stents have shown acceptable results for the various reasons inherent to these approaches. Although some studies showed POBA and the deployment of bare stents to be equally effective with respect to restenosis, in a recently published meta-analysis of eleven trials the restenosis rates were as high as 25.8 % for POBA and 34.2 % for bare stents, respectively.

Brachytherapy initially demonstrated encouraging results. However, due to its disadvantages such as delayed endothelialization, the risk associated with additional stenting, the cumbersome logistics at the sites and in the labs, brachytherapy is not considered as a valid approach. Data with the Sirolimus-eluting Cypher™ stent in vessels averaging 2.60 ± 0.54 mm in diameter showed the benefit of this cytostatic drug in this indication. However, this approach introduces a layer of metal to the per se small vessel and, thus, reduces the vascular lumen.

Study Rationale:

Since none of the above mentioned options for the percutaneous treatment of small vessel coronary artery stenoses seems to be universally recommendable the Paclitaxel-eluting PTCA balloon catheter has to be considered as an alternative. The possible advantages over either the uncoated balloon or bare stent include the antiproliferative mode of action of the compound. In comparison to the drug eluting stents (DES) the homogenous distribution of the compound along the target vessel segment, the lack of chronic mechanical alteration of the artery and the ease of access to the lesion would favor the Paclitaxel-eluting balloon.

However, there are no data available on the use of the drug eluting balloons in small vessel disease and the information on the other indication evaluated to date, the treatment of in-stent restenosis is limited. In the latter indication, the animal model and according to unpublished results in humans, the proliferation induced by a Paclitaxel-eluting balloon catheter was significantly less compared to an uncoated balloon, the Paclitaxel-coated Taxus™ stent, and to the Sirolimus-eluting Cypher™ stent. Therefore, it is prudent to test the Paclitaxel-eluting PTCA balloon catheter as an alternative approach for the percutaneous transluminal treatment of small vessel coronary artery lesions.

Since none of the alternative methods has unequivocally shown its superiority over the other, none of them may serve as the golden standard and, i.e., for direct comparison. Consequently, as the initial step conducting a single arm study with the Paclitaxel-eluting balloon is suggested with historic data serving for comparison. Once these results will have been obtained a prospective randomized trial shall be discussed.

Enrollment

120 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia
Patients eligible for coronary revascularization by means of PCI
Patients suitable for coronary revascularization of any sort (balloon angioplasty, device-assisted balloon-angioplasty or coronary artery bypass grafting)
Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the first year following the study procedure. Hence, patients will be advised to use an adequate birth control method up to and including 6 months follow-up.
Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol
Patients must agree to undergo the 6 months angiographic follow-up
Patients must agree to undergo the 1 and 3 year clinical follow-up
Patient is able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial, e.g., balloon angioplasty by means of the Paclitaxel-eluting PTCA-balloon catheter. The patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document
Patients with medical indication for follow-up angiography
Reference diameters from 2.25 mm to 2.8 mm and ≤ 22 mm in length
Diameter stenosis pre procedure must be either > 70 % or >50 % if ischemia corresponding to the target lesion is documented either by exercise stress ECG, stress echocardiography, or scintigraphy
The target lesion must be covered by a single Paclitaxel-eluting balloon

Exclusion criteria

Patients with acute (< 24 h) or recent (≤ 48 hours) myocardial infarction
Patients with unstable angina pectoris (Braunwald class 3)
Patients with severe congestive heart failure
Patients with severe heart failure NYHA IV
Patients demonstrating clinical signs of cardiogenic shock at the time of the procedure (systolic blood pressure of less than 80 mm Hg requiring inotropic support, IABP and/or fluid challenge).
Women who are pregnant or lactating
Patients with another coronary stent implanted previously into the target vessel
Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated
Patient participates in other clinical trials involving any investigational device or drug
Untreated hyperthyroidism
Patient has presence or history of severe renal failure (GFR<30ml/min) and is therefore not eligible for angiography. Patient's serum creatinine levels must be documented
Post transplantation of any organ or immune suppressive medication
Other disease to jeopardize follow-up (e.g., malignoma)
Addiction to any drug or to alcohol
Patients with any type of surgery during the week preceding the interventional procedure
Evidence of extensive thrombosis within target vessel before the intervention
Side branch > 2 mm in diameter originating from the lesion
Bifurcate lesion
Restenotic lesion
Multilesion percutaneous coronary intervention within the same artery (a main artery (e.g., LCdx) and its side branch (e.g., OMS) are considered as different arteries)
Percutaneous coronary intervention of venous graft
Target segment is occluded (i.e., acute or chronic)
In-stent restenosis
Ostial lesion within 2 mm of vessel origin
Patient is intolerant to aspirin and/or the ADP-antagonists clopidogrel or has a history of neutropenia, thrombocytopenia induced by ADP-antagonists, or severe hepatic dysfunction prohibiting the use of clopidogrel